Humulin M3 Kwikpen (Mixture 3) (Insulin Human (Rdna))

Humulin M3 Kwikpen is indicated for the treatment of diabetes mellitus where a mixed insulin regimen is appropriate.

• Type 1 diabetes mellitus requiring basal and prandial insulin coverage.
• Type 2 diabetes mellitus inadequately controlled with oral agents alone.
• Adults and children (≥2 years) who benefit from a fixed 30 % NPH / 70 % regular ratio.
• Situations where a single daily injection simplifies therapy compared with separate basal and rapid‑acting injections.
• Use as part of a comprehensive diabetes management plan that includes diet, exercise and glucose monitoring.

• Humulin M3 contains recombinant human insulin that binds to insulin receptors on muscle, adipose and hepatic cells. Receptor activation triggers autophosphorylation and downstream signaling through the PI3‑K/Akt pathway, promoting translocation of GLUT‑4 transporters to the cell surface and increasing glucose uptake. In the liver, insulin suppresses gluconeogenesis and glycogenolysis, reducing endogenous glucose production. The NPH component provides prolonged basal activity, while the regular insulin component supplies rapid prandial action.

Adverse reactions to Humulin M3 Kwikpen are reported in clinical practice and may vary in frequency and severity.

Common

• Hypoglycemia, presenting as sweating, tremor, confusion or loss of consciousness.
• Injection site reactions such as redness, swelling, or itching.
• Lipodystrophy, including lipoatrophy or lipohypertrophy at the injection site.
• Weight gain associated with improved glycemic control.
• Nausea or mild gastrointestinal discomfort.
• Visual disturbances such as blurred vision during rapid glucose changes.

Serious

• Severe hypoglycemia requiring assistance.
• Allergic reactions ranging from urticaria to anaphylaxis.
• Edema or heart failure exacerbation in susceptible patients.
• Persistent hyperglycemia indicating insulin resistance or dosing error.
• Acute pancreatitis presenting with abdominal pain and elevated enzymes.
• Severe local infection at the injection site, including cellulitis.

When prescribing or using Humulin M3 Kwikpen, clinicians and patients should consider several safety precautions to minimize risks and ensure effective therapy.

• Assess renal and hepatic function before initiating therapy and adjust dose as needed.
• Monitor blood glucose regularly to detect hypoglycemia or hyperglycemia early.
• Educate patients on proper injection technique and rotation of sites to prevent lipodystrophy.
• Review concomitant medications that may mask hypoglycemia symptoms, such as beta‑blockers.
• Use caution in pregnant or breastfeeding women; insulin is category B but glycemic control remains essential.
• Avoid use in patients with known hypersensitivity to human insulin or any excipients.
• Consider cardiovascular status, as rapid glucose shifts can affect heart failure patients.

Humulin M3 Kwikpen may interact with other drugs that influence glucose metabolism or insulin action, requiring attention to avoid adverse outcomes.

Avoid

• Concurrent use of high‑dose sulfonylureas or meglitinides, which can markedly increase hypoglycemia risk.
• Administration of systemic corticosteroids without adjusting insulin dose, as they raise blood glucose.
• Co‑administration with MAO‑B inhibitors that may potentiate insulin’s glucose‑lowering effect.

Use with caution

• Beta‑blockers may mask hypoglycemia symptoms; monitor glucose closely.
• ACE inhibitors and ARBs generally safe but require periodic renal function checks.
• Loop diuretics can cause electrolyte shifts affecting insulin sensitivity.
• Alcohol intake can potentiate insulin action and precipitate hypoglycemia.